Systematic literature review shows low risk of safety concerns or loss of efficacy after switching to a biosimilar
In a review of 90 studies involving 14,255 unique patients the authors found there were no reported increases in treatment-related safety events—including loss of efficacy—related to switching. “Thus, the extensive data collected to date suggest that the act of switching from a reference medicine to a biosimilar is not inherently dangerous, and that patients, healthcare professionals, and the public should not assume that it is problematic,” say the authors.